CRYSTALLBrain: Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage

Sponsor
University Hospital Inselspital, Berne (Other)
Overall Status
Recruiting
CT.gov ID
NCT04043598
Collaborator
(none)
320
1
2
21.3
15.1

Study Details

Study Description

Brief Summary

Patients with subarachnoid hemorrhage are prone to suffer from dysnatriemia. Evidence shows that hyponatriemia is associated with increased incidence of vasospasm, brain swelling and mortality in these patients. Patients with subarachnoid hemorrhage often require large amounts of iv fluids in order to maintain euvolemia and support cardiocirculatory function. Prior evidence shows that the type of infusion fluid significantly influences blood sodium content. Hence, this study evaluated whether the sodium content of the infusion solution impacts mortality and morbidity in patients with subarachnoid hemorrhage.

Condition or Disease Intervention/Treatment Phase
  • Drug: 0.9% Sodium-chloride
  • Drug: Ringer's Lactate
N/A

Detailed Description

Background: Despite ongoing advances in critical care mortality and morbidity of patients with subarachnoid hemorrhage remains high. Secondary brain injuries related to cerebral vasospasm and consecutive ischemic brain injury and intracerebral edema are the main contributors to mortality and morbidity in these patients. Evidence points towards low serum sodium levels being one of the significant risk factors for of secondary brain injury in this population. Previous studies show that fluid resuscitation with normal saline results in higher serum sodium levels and higher serum osmolality when compared to balanced infusates in patients with subarachnoid hemorrhage.

Aim: The primary objective of this study is to evaluate whether the use of a sodium-rich infusion (normal saline) results in better clinical outcome when compared to a sodium-depleted infusion (lactated Ringer's) in patients with subarachnoid hemorrhage. The primary endpoint will be the occurrence of clinically relevant vasospasm requiring immediate treatment. In addition, the investigators will assess other relevant complications such as long and short-term mortality, significant brain edema requiring conservative therapy or/and operative hemicraniectomy, as well as further patient-relevant outcomes such as days on organ support, postoperative infections, length of stay and long-term disability/mortality.

Study intervention: All patients admitted to a participating hospital with the diagnosis of intracerebral bleeding will be screened and if eligible, randomized to one of the study arms. Individual patient's consent will be sought. Thereafter, patients will receive only the allocated study fluid for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge. Neurological evaluation will be performed hourly for the initial phase and thereafter two hourly. Serum sodium, osmolality, fluid, water and electrolyte balance as well as acid-base homeostasis will be evaluated daily. Further, specific assessment of renal, cardiac and immune function takes place at 5 pre-specified time-points (day 1,3,7,10 and at ICU/IMC discharge).

After ICU/IMC discharge patients will be followed for evaluation of secondary endpoints. Long-term disability will be assessed by telephone interview based on the modified the Rankin-Scale and the Glasgow Outcome Scale Extended.

Sample Size: Sample size calculation was based upon the investigators' ICU's registry data. In 2017, 44.38% patients with subarachnoid hemorrhage reached the predefined endpoint of clinically relevant vasospasm requiring immediate intervention. A clinically relevant effect size was determined to be an improvement in outcome of 15%. Based on these results a patient number of n = 160 for each group was determined under estimation of a 15% drop out rate.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
320 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Multi-center investigator-initiated randomized-controlled double blind clinical trial comparing to already established treatment protocols.Multi-center investigator-initiated randomized-controlled double blind clinical trial comparing to already established treatment protocols.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
double-blind randomized
Primary Purpose:
Other
Official Title:
Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage - a Multi-center Randomized Double-blind Clinical Trial
Actual Study Start Date :
May 24, 2022
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: high sodium infusion fluid

Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.

Drug: 0.9% Sodium-chloride
We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.

Active Comparator: low sodium infusion fluid

Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.

Drug: Ringer's Lactate
We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.

Outcome Measures

Primary Outcome Measures

  1. Number of patients with clinically relevant vasospasms [From ICU admission until discharge (usually within the first 21 days)]

    Defined as new neurologic deficit requiring immediate intervention

Secondary Outcome Measures

  1. Number of ICU deaths [From ICU admission until discharge (usually within the first 21 days)]

    Death on the ICU

  2. Number of In-hospital deaths [From hospital admission to hospital discharge (usually within the first 21 days)]

    Death during hospital stay

  3. Number of severe vasospasms requiring endovascular treatment [From hospital admission to hospital discharge (usually within the first 21 days)]

  4. Number of patients needing decompressive hemicraniectomy [From hospital admission to hospital discharge (usually within the first 21 days)]

    Operative intervention needed for high intracranial pressure

  5. Difference in modified RankingScale [At day 90 and 180]

    Scale ranges from 0-5 (0 = no symptoms; 5= severe disability)

  6. Difference in Glasgow Outcome Scale [At day 90 and 180]

    Scale ranges from 1-8 (1 is dead 7 good recovery)

  7. Difference in mini Montreal Cognitive Assessment [At day 90 and 180]

    miniMOCA at 90 and 180 days

  8. Difference in Long-term mortality [At day 90 and 180]

    Death at 90 and 180 day

  9. Length of stay [ICU stay and hospital stay (usually between 1-30days)]

    Length of hospital stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

All adult patients suffering from non-traumatic subarachnoid haemorrhage.

Exclusion Criteria:
  • Patients with major intra-cranial trauma

  • Diagnosis of an AV-malformation as the source of subarachnoid hemorrhage on the primary CT/MRI or angiography

  • More than 24 hours after diagnosis of subarachnoid haemorrhage as diagnosed by cerebral imaging (CT scan or MRI)

  • Patients with clear limitation to therapy at hospital admission (eg ICU admission for evaluation of organ donation)

  • Declining of informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland Bern Switzerland 3010

Sponsors and Collaborators

  • University Hospital Inselspital, Berne

Investigators

  • Principal Investigator: Anna S Messmer, MD, Department of Intensive Care, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier:
NCT04043598
Other Study ID Numbers:
  • CRYSTALLBrain
First Posted:
Aug 2, 2019
Last Update Posted:
May 27, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2022